vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $220.8M, roughly 1.3× UNIVERSAL TECHNICAL INSTITUTE INC). UNIVERSAL TECHNICAL INSTITUTE INC runs the higher net margin — 5.8% vs -45.7%, a 51.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.6%). UNIVERSAL TECHNICAL INSTITUTE INC produced more free cash flow last quarter ($-19.2M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.5%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
GH vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $220.8M |
| Net Profit | $-128.5M | $12.8M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 7.1% |
| Net Margin | -45.7% | 5.8% |
| Revenue YoY | 39.4% | 9.6% |
| Net Profit YoY | -15.8% | -42.1% |
| EPS (diluted) | $-1.01 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $220.8M | ||
| Q3 25 | $265.2M | $222.4M | ||
| Q2 25 | $232.1M | $204.3M | ||
| Q1 25 | $203.5M | $207.4M | ||
| Q4 24 | $201.8M | $201.4M | ||
| Q3 24 | $191.5M | $196.4M | ||
| Q2 24 | $177.2M | $177.5M | ||
| Q1 24 | $168.5M | $184.2M |
| Q4 25 | $-128.5M | $12.8M | ||
| Q3 25 | $-92.7M | $18.8M | ||
| Q2 25 | $-99.9M | $10.7M | ||
| Q1 25 | $-95.2M | $11.4M | ||
| Q4 24 | $-111.0M | $22.2M | ||
| Q3 24 | $-107.8M | $18.8M | ||
| Q2 24 | $-102.6M | $5.0M | ||
| Q1 24 | $-115.0M | $7.8M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 7.1% | ||
| Q3 25 | -37.3% | 11.2% | ||
| Q2 25 | -45.9% | 6.9% | ||
| Q1 25 | -54.6% | 8.1% | ||
| Q4 24 | -62.4% | 13.6% | ||
| Q3 24 | -61.3% | 13.3% | ||
| Q2 24 | -56.8% | 4.2% | ||
| Q1 24 | -59.2% | 6.1% |
| Q4 25 | -45.7% | 5.8% | ||
| Q3 25 | -35.0% | 8.4% | ||
| Q2 25 | -43.0% | 5.2% | ||
| Q1 25 | -46.8% | 5.5% | ||
| Q4 24 | -55.0% | 11.0% | ||
| Q3 24 | -56.3% | 9.6% | ||
| Q2 24 | -57.9% | 2.8% | ||
| Q1 24 | -68.2% | 4.2% |
| Q4 25 | $-1.01 | $0.23 | ||
| Q3 25 | $-0.74 | $0.33 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $0.21 | ||
| Q4 24 | $-0.90 | $0.40 | ||
| Q3 24 | $-0.88 | $0.35 | ||
| Q2 24 | $-0.84 | $0.09 | ||
| Q1 24 | $-0.94 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $162.8M |
| Total DebtLower is stronger | $1.5B | $101.4M |
| Stockholders' EquityBook value | $-99.3M | $335.9M |
| Total Assets | $2.0B | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $162.8M | ||
| Q3 25 | $580.0M | $169.1M | ||
| Q2 25 | $629.1M | $70.7M | ||
| Q1 25 | $698.6M | $96.0M | ||
| Q4 24 | $525.5M | $172.0M | ||
| Q3 24 | $585.0M | $161.9M | ||
| Q2 24 | $933.7M | $115.5M | ||
| Q1 24 | $1.0B | $116.1M |
| Q4 25 | $1.5B | $101.4M | ||
| Q3 25 | $1.1B | $87.1M | ||
| Q2 25 | $1.1B | $73.8M | ||
| Q1 25 | $1.1B | $94.4M | ||
| Q4 24 | $1.1B | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $-99.3M | $335.9M | ||
| Q3 25 | $-354.5M | $328.1M | ||
| Q2 25 | $-305.5M | $306.8M | ||
| Q1 25 | $-250.8M | $293.9M | ||
| Q4 24 | $-139.6M | $280.0M | ||
| Q3 24 | $-60.1M | $260.2M | ||
| Q2 24 | $-1.6M | $239.4M | ||
| Q1 24 | $68.3M | $232.6M |
| Q4 25 | $2.0B | $834.0M | ||
| Q3 25 | $1.3B | $826.1M | ||
| Q2 25 | $1.3B | $740.8M | ||
| Q1 25 | $1.3B | $720.4M | ||
| Q4 24 | $1.5B | $753.8M | ||
| Q3 24 | $1.5B | $744.6M | ||
| Q2 24 | $1.6B | $706.0M | ||
| Q1 24 | $1.7B | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $3.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $-19.2M |
| FCF MarginFCF / Revenue | -19.3% | -8.7% |
| Capex IntensityCapex / Revenue | 9.9% | 10.1% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $3.1M | ||
| Q3 25 | $-35.4M | $57.1M | ||
| Q2 25 | $-60.3M | $18.1M | ||
| Q1 25 | $-62.7M | $-789.0K | ||
| Q4 24 | $-64.5M | $23.0M | ||
| Q3 24 | $-51.1M | $67.5M | ||
| Q2 24 | $-94.0M | $10.0M | ||
| Q1 24 | $-30.3M | $-2.5M |
| Q4 25 | $-54.2M | $-19.2M | ||
| Q3 25 | $-45.8M | $40.6M | ||
| Q2 25 | $-65.9M | $6.8M | ||
| Q1 25 | $-67.1M | $-11.7M | ||
| Q4 24 | $-83.4M | $19.6M | ||
| Q3 24 | $-55.3M | $60.0M | ||
| Q2 24 | $-99.1M | $3.0M | ||
| Q1 24 | $-37.2M | $-8.4M |
| Q4 25 | -19.3% | -8.7% | ||
| Q3 25 | -17.3% | 18.3% | ||
| Q2 25 | -28.4% | 3.4% | ||
| Q1 25 | -33.0% | -5.7% | ||
| Q4 24 | -41.3% | 9.7% | ||
| Q3 24 | -28.9% | 30.6% | ||
| Q2 24 | -55.9% | 1.7% | ||
| Q1 24 | -22.1% | -4.6% |
| Q4 25 | 9.9% | 10.1% | ||
| Q3 25 | 3.9% | 7.4% | ||
| Q2 25 | 2.4% | 5.5% | ||
| Q1 25 | 2.2% | 5.3% | ||
| Q4 24 | 9.4% | 1.7% | ||
| Q3 24 | 2.2% | 3.8% | ||
| Q2 24 | 2.9% | 4.0% | ||
| Q1 24 | 4.1% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | — | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
